Crescent Biopharma
CBIO
30 hedge funds and large institutions have $174M invested in Crescent Biopharma in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 20 closing their positions.
2,587% more capital invested
Capital invested by funds: $6.46M → $174M (+$167M)
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
7.46% more ownership
Funds ownership: 47.68% → 55.14% (+7.5%)
14% less funds holding
Funds holding: 35 → 30 (-5)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.9M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$29.4M |
| 3 |
VA
VR Adviser
New York
|
+$28.7M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$27.3M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$561K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$120K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$93.8K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$80.3K |
| 5 |
SC
Shay Capital
New York
|
-$74.9K |
CBIO Hedge Fund Activity: Q2 2025 in Review
30 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2025, worth a combined $174M — up 2,587% from $6.46M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CBIO and 15 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $29.9M. The largest seller was Vanguard Group, exiting entirely with an estimated $561K sold.
- 30 institutional investors held Crescent Biopharma (CBIO) as of Q2 2025, down from 35 in Q1 2025.
- Funds reported $174M of Crescent Biopharma stock for Q2 2025, up 2,587% quarter-over-quarter.
- 15 funds opened new Crescent Biopharma positions in Q2 2025 and 20 closed out, a net change of -5 holders.
- The largest Crescent Biopharma buyer in Q2 2025 was Fidelity Investments, an estimated $29.9M added.
- The largest Crescent Biopharma seller in Q2 2025 was Vanguard Group, an estimated $561K sold.
Based on aggregated 13F filings for Q2 2025.